Compare DAIO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | GDTC |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 24.8M |
| IPO Year | N/A | 2023 |
| Metric | DAIO | GDTC |
|---|---|---|
| Price | $3.06 | $1.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.22 | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 79.1K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,701,000.00 | $573,193.00 |
| Revenue This Year | $9.14 | $5.37 |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $1.88 | $1.50 |
| 52 Week High | $3.57 | $4.05 |
| Indicator | DAIO | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 37.67 |
| Support Level | $2.86 | $1.71 |
| Resistance Level | $3.20 | $1.68 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 74.56 | 15.32 |
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.